Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Phill Febbo, Henry Fuchs, Woodrow Myers, Bob Holland

Premium

Genomic Health announced that Phill Febbo has joined the firm as its new chief medical officer. Febbo is an experienced physician scientist who was previously a professor of medicine and urology at the University of California, San Francisco. He will report to Steve Shak, Genomic Health's executive VP of R&D.

Additionally, Henry Fuchs, executive VP and CMO of Biomarin, has joined Genomic Health's board of directors. He has previously held leadership roles at Onyx and Genentech.

Woodrow Myers, managing director of Myers Ventures, will step down from his seven-year tenure on Genomic Health's board. Myers will now be CEO of Corizon, a provider of correctional healthcare services.


Oxford Gene Technology has named Bob Holland to be its new chief medical officer, the company said this week. Holland helped to create and was VP and head of AstraZeneca's Personalized Healthcare and Biomarkers division. In his new role, Holland will lead clinical affairs across OGT's business areas, including working with R&D and commercial teams to develop clinical development programs to expand the company's next-generation sequencing and microarray cancer profiling solutions, and its biomarker programs for prostate and colorectal cancers.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.